Angiotensin receptor-neprilysin inhibitors: clinical potential in heart failure and beyond

References

• KempCDConteJVThe pathophysiology of heart failureCardiovasc Pathol201321536537122227365
   PubMed Web of Science ®Google Scholar
• TanYTWenzelburgerFLeeEThe pathophysiology of heart failure with normal ejection fraction exercise echocardiography reveals complex abnormalities of both systolic and diastolic ventricular function involving torsion, untwist, and longitudinal motionJ Am Coll Cardiol2009541364619555838
   PubMed Web of Science ®Google Scholar
• BorlaugBAOlsonTPLamCSGlobal cardiovascular reserve dysfunction in heart failure with preserved ejection fractionJ Am Coll Cardiol2010561184585420813282
   PubMed Web of Science ®Google Scholar
• ZileMRBaicuCFBonnemaDDDiastolic heart failure: definitions and terminologyProg Cardiovasc Dis200547530731316003645
   PubMed Web of Science ®Google Scholar
• ZileMRBaicuCFGaaschWHDiastolic heart failure – abnormalities in active relaxation and passive stiffness of the left ventricleN Engl J Med2004350191953195915128895
   PubMed Web of Science ®Google Scholar
• WestermannDLindnerDKasnerMCardiac inflammation contributes to changes in the extracellular matrix in patients with heart failure and normal ejection fractionCirc Heart Fail201141445221075869
   PubMed Web of Science ®Google Scholar
• VasanRSLarsonMGBenjaminEJEvansJCReissCKLevyDCongestive heart failure in subjects with normal versus reduced left ventricular ejection fraction prevalence and mortality in a population-based cohortJ Am Coll Cardiol19993371948195510362198
   PubMed Web of Science ®Google Scholar
• BhatiaRSTuJVLeeDSOutcome of heart failure with preserved ejection fraction in a population-based studyN Engl J Med2006355326026916855266
   PubMed Web of Science ®Google Scholar
• CohnJNJohnsonGHeart failure with normal ejection fraction The V-HeFT Study. Veterans Administration Cooperative Study GroupCirculation1990812 SupplIII48III532404638
   PubMed Web of Science ®Google Scholar
• Digitalis Investigation GroupThe effect of digoxin on mortality and morbidity in patients with heart failureN Engl J Med199733685255339036306
   PubMed Web of Science ®Google Scholar
• YancyCWJessupMBozkurtB2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice GuidelinesJ Am Coll Cardiol20136216e147e23923747642
   PubMed Web of Science ®Google Scholar
• McMurrayJJAdamopoulosSAnkerSDESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012Eur J Heart Fail201214880386922828712
   PubMed Web of Science ®Google Scholar
• Rose-JonesLJRommelJJChangPPHeart failure with preserved ejection fraction: an ongoing enigmaCardiol Clin2014321151-x24286586
   PubMed Web of Science ®Google Scholar
• LindenfeldJAlbertNMBoehmerJPHFSA 2010 Comprehensive Heart Failure Practice GuidelineJ Card Fail2010166475539
   Web of Science ®Google Scholar
• ClelandJGTenderaMAdamusJFreemantleNPolonskiLTaylorJThe perindopril in elderly people with chronic heart failure (PEP-CHF) studyEur Heart J200627192338234516963472
   PubMed Web of Science ®Google Scholar
• MassieBMCarsonPEMcMurrayJJVIrbesartan in patients with heart failure and preserved ejection fractionN Engl J Med2008359232456246719001508
   PubMed Web of Science ®Google Scholar
• YusufSPfefferMASwedbergKEffects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved TrialLancet2003362938677778113678871
   PubMed Web of Science ®Google Scholar
• EdelmannFWachterRSchmidtAGEffect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the ALDO-DHF randomized controlled trialJAMA2013309878179123443441
   PubMed Web of Science ®Google Scholar
• PittBPfefferMAAssmannSFSpironolactone for heart failure with preserved ejection fractionN Engl J Med2014370151383139224716680
   PubMed Web of Science ®Google Scholar
• GoASMozaffarianDRogerVLHeart Disease and Stroke Statistics – 2014 update: a report from the American Heart AssociationCirculation20141293e28e29224352519
   PubMed Web of Science ®Google Scholar
• McMurrayJJVPfefferMAHeart failureLancet200536594741877188915924986
   PubMed Web of Science ®Google Scholar
• SayerGBhatGThe renin-angiotensin-aldosterone system and heart failureCardiol Clin201432121-vii24286576
   PubMed Web of Science ®Google Scholar
• CrowleySDGurleySBHerreraMJAngiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidneyProc Natl Acad Sci U S A200610347179851799017090678
   PubMed Web of Science ®Google Scholar
• GrayMOLongCSKalinyakJELiH-TKarlinerJSAngiotensin II stimulates cardiac myocyte hypertrophy via paracrine release of TGF-β1 and endothelin-1 from fibroblastsCardiovasc Res19984023523639893729
   PubMed Web of Science ®Google Scholar
• LorellBHCarabelloBALeft ventricular hypertrophy: pathogenesis, detection, and prognosisCirculation2000102447047910908222
   PubMed Web of Science ®Google Scholar
• WeberKTExtracellular matrix remodeling in heart failure: a role for de novo angiotensin II generationCirculation19979611406540829403633
   PubMed Web of Science ®Google Scholar
• PengJGurantzDTranVCowlingRTGreenbergBHTumor necrosis factor-α-induced AT1 receptor upregulation enhances angiotensin II-mediated cardiac fibroblast responses that favor fibrosisCirc Res200291121119112612480812
   PubMed Web of Science ®Google Scholar
• BartBATreatment of congestion in congestive heart failure: ultrafiltration is the only rational initial treatment of volume overload in decompensated heart failureCirc Heart Fail20092549950419808381
   PubMed Web of Science ®Google Scholar
• SchrierRWRole of diminished renal function in cardiovascular mortality: marker or pathogenetic factor?J Am Coll Cardiol20064711816386657
   PubMed Web of Science ®Google Scholar
• AtlasSAThe renin-angiotensin aldosterone system: pathophysiological role and pharmacologic inhibitionJ Manag Care Pharm2007138S917605505
   PubMed Web of Science ®Google Scholar
• McKiePBurnettJJrRationale and therapeutic opportunities for natriuretic peptide system augmentation in heart failureCurr Heart Fail Rep201512171425331110
   PubMedGoogle Scholar
• ThibaultGAmiriFGarciaRRegulation of natriuretic peptide secretion by the heartAnnu Rev Physiol199961119321710099687
   PubMedGoogle Scholar
• SteinBCLevinRINatriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart diseaseAm Heart J199813559149239588425
   PubMed Web of Science ®Google Scholar
• GackowskiAIsnardRGolmardJ-LComparison of echocardiography and plasma B-type natriuretic peptide for monitoring the response to treatment in acute heart failureEur Heart J200425201788179615474693
   PubMed Web of Science ®Google Scholar
• NathisuwanSTalbertRLA review of vasopeptidase inhibitors: a new modality in the treatment of hypertension and chronic heart failurePharmacotherapy2002221274211794428
   PubMed Web of Science ®Google Scholar
• MoyesAJKhambataRSVillarIEndothelial C-type natriuretic peptide maintains vascular homeostasisJ Clin Invest201412494039405125105365
   PubMed Web of Science ®Google Scholar
• CheungBYKumanaCRNatriuretic peptides – relevance in cardiovascular diseaseJAMA199828023198319849863839
   PubMed Web of Science ®Google Scholar
• LisyOJougasakiMHeubleinDMRenal actions of synthetic dendroaspis natriuretic peptideKidney Int199956250250810432389
   PubMed Web of Science ®Google Scholar
• SugaSNakaoKHosodaKReceptor selectivity of natriuretic peptide family, atrial natriuretic peptide, brain natriuretic peptide, and C-type natriuretic peptideEndocrinology199213012292391309330
   PubMed Web of Science ®Google Scholar
• HanksSKQuinnAMHunterTThe protein kinase family: conserved features and deduced phylogeny of the catalytic domainsScience1988241486142523291115
   PubMed Web of Science ®Google Scholar
• ChinkersMGarbersDLThe protein kinase domain of the ANP receptor is required for signalingScience19892454924139213942571188
   PubMed Web of Science ®Google Scholar
• GrafKKoehnePGräfeMZhangMAuch-SchwelkWFleckERegulation and differential expression of neutral endopeptidase 24.11 in human endothelial cellsHypertension19952622302357635530
   PubMed Web of Science ®Google Scholar
• VannesteYMichelADimalineRNajdovskiTDeschodt-LanckmanMHydrolysis of alpha-human atrial natriuretic peptide in vitro by human kidney membranes and purified endopeptidase-24.11. Evidence for a novel cleavage siteBiochem J198825425315372972276
   PubMed Web of Science ®Google Scholar
• YoungJBAbrahamWTStevensonLWHortonDPResults of the VMAC trial: vasodilation in the management of acute congestive heart failureCirculation20001022227942794
   Google Scholar
• Cardiorentis. TRUE-AHF Phase III clinical trial Available from: http://www.cardiorentis.com/de/rd/true-ahf.phpAccessed January 26, 2015
   Google Scholar
• AhmadTFelkerGMSubcutaneous B-type natriuretic peptide for treatment of heart failure: a dying therapy reborn?J Am Coll Cardiol201260222313231523122792
   PubMed Web of Science ®Google Scholar
• ChenHHGlocknerJFSchirgerJACataliottiARedfieldMMBurnettJCNovel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptideJ Am Coll Cardiol201260222305231223122795
   PubMed Web of Science ®Google Scholar
• McKiePMCataliottiABoerrigterGA novel atrial natriuretic peptide based therapeutic in experimental angiotensin II mediated acute hypertensionHypertension20105661152115920975033
   PubMed Web of Science ®Google Scholar
• LisyOHuntleyBKMcCormickDJKurlanskyPABurnettJCDesign, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NPJ Am Coll Cardiol2008521606818582636
   PubMed Web of Science ®Google Scholar
• ChenHHHeart failure: a state of brain natriuretic peptide deficiency or resistance or both!*J Am Coll Cardiol200749101089109117349889
   PubMed Web of Science ®Google Scholar
• Natrecor^® [Product Information]Fremont, CA, USAScios Inc2013 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/20920s033lbl.pdf
   Google Scholar
• ColucciWSElkayamUHortonDPIntravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study GroupN Engl J Med2000343424625310911006
   PubMed Web of Science ®Google Scholar
• SilverMAHortonDPGhaliJKElkayamUEffect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failureJ Am Coll Cardiol200239579880311869844
   PubMed Web of Science ®Google Scholar
• BurgerAJHortonDPLeJemtelTEffect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT studyAm Heart J200214461102110812486437
   PubMed Web of Science ®Google Scholar
• KesselheimASFischerMAAvornJThe rise and fall of Natrecor for congestive heart failure: implications for drug policyHealth Aff (Millwood)20062541095110216835191
   PubMed Web of Science ®Google Scholar
• Sackner-BernsteinJDKowalskiMFoxMAaronsonKShort-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trialsJAMA2005293151900190515840865
   PubMed Web of Science ®Google Scholar
• Sackner-BernsteinJDSkopickiHAAaronsonKDRisk of worsening renal function with nesiritide in patients with acutely decompensated heart failureCirculation2005111121487149115781736
   PubMed Web of Science ®Google Scholar
• HernandezAFO’ConnorCMStarlingRCRationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)Am Heart J2009157227127719185633
   PubMed Web of Science ®Google Scholar
• O’ConnorCMStarlingRCHernandezAFEffect of nesiritide in patients with acute decompensated heart failureN Engl J Med20113651324321732835
   PubMed Web of Science ®Google Scholar
• GottliebSSStebbinsAVoorsAAEffects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure)J Am Coll Cardiol201362131177118323747790
   PubMed Web of Science ®Google Scholar
• RichardsAMVasopeptidase inhibitors for heart failure: where do we go from here?Eur J Heart Fail20035441141312921800
   PubMed Web of Science ®Google Scholar
• LangCCMotwaniJCoutieWJStruthersADInfluence of candoxatril on plasma brain natriuretic peptide in heart failureLancet199133887612551676808
   PubMed Web of Science ®Google Scholar
• NorthridgeDBJardineAGAlabasterCTEffects of UK 69 578: a novel atriopeptidase inhibitorLancet1989286635915932570286
   PubMed Web of Science ®Google Scholar
• ErdosEGSkidgelRANeutral endopeptidase 24.11 (enkephalinase) and related regulators of peptide hormonesFASEB J1989321451512521610
   PubMed Web of Science ®Google Scholar
• KahnJCPateyMDubois-RandeJLEffect of sinorphan on plasma atrial natriuretic factor in congestive heart failureLancet199033586811181191967410
   PubMed Web of Science ®Google Scholar
• NorthridgeDBCurriePFNewbyDEPlacebo-controlled comparison of candoxatril, an orally active neutral endopeptidase inhibitor, and captopril in patients with chronic heart failureEur J Heart Fail199911677210937982
   PubMed Web of Science ®Google Scholar
• NorthridgeDBNewbyDERooneyENorrieJDargieHJComparison of the short-term effects of candoxatril, an orally active neutral endopeptidase inhibitor, and frusemide in the treatment of patients with chronic heart failureAm Heart J19991386 Pt 11149115710577447
   PubMed Web of Science ®Google Scholar
• WestheimASBostromPChristensenCCParikkaHRykkeEOToivonenLHemodynamic and neuroendocrine effects for candoxatril and frusemide in mild stable chronic heart failureJ Am Coll Cardiol19993461794180110577572
   PubMed Web of Science ®Google Scholar
• BevanEGConnellJMDoyleJCandoxatril, a neutral endopeptidase inhibitor: efficacy and tolerability in essential hypertensionJ Hypertens19921076076131321186
   PubMed Web of Science ®Google Scholar
• AndoSRahmanMAButlerGCSennBLFlorasJSComparison of candoxatril and atrial natriuretic factor in healthy men. Effects on hemodynamics, sympathetic activity, heart rate variability, and endothelinHypertension1995266 Pt 2116011667498988
   PubMed Web of Science ®Google Scholar
• RichardsAMWittertGACrozierIGChronic inhibition of endopeptidase 24.11 in essential hypertension: evidence for enhanced atrial natriuretic peptide and angiotensin IIJ Hypertens19931144074168390508
   PubMed Web of Science ®Google Scholar
• FerroCJSprattJCHaynesWGWebbDJInhibition of neutral endopeptidase causes vasoconstriction of human resistance vessels in vivoCirculation19989723232323309639376
   PubMed Web of Science ®Google Scholar
• KentschMOtterWDrummerCNotgesAGerzerRMuller-EschGNeutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failureEur J Clin Pharmacol1996513–42692729010697
   PubMed Web of Science ®Google Scholar
• MangiaficoSCostello-BoerrigterLCAndersenIACataliottiABurnettJCNeutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeuticsEur Heart J2013341288689322942338
   PubMed Web of Science ®Google Scholar
• RouleauJLPfefferMAStewartDJComparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trialLancet2000356923061562010968433
   PubMed Web of Science ®Google Scholar
• PackerMCaliffRMKonstamMAComparison of omapatrilat and enalapril in patients with chronic heart failure: the Omapatrilat Versus Enalapril Randomized Trial of Utility in Reducing Events (OVERTURE)Circulation2002106892092612186794
   PubMed Web of Science ®Google Scholar
• KostisJBPackerMBlackHRSchmiederRHenryDLevyEOmapatrilat and enalapril in patients with hypertension: the Omapatrilat Cardiovascular Treatment vs. Enalapril (OCTAVE) trialAm J Hypertens200417210311114751650
   PubMed Web of Science ®Google Scholar
• PickeringTGThe rise and fall of omapatrilatJ Clin Hypertens200245371373
   Google Scholar
• ByrdJBTouzinKSileSDipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedemaHypertension200851114114718025295
   PubMed Web of Science ®Google Scholar
• LangCCStruthersADTargeting the renin-angiotensin-aldosterone system in heart failureNat Rev Cardiol201310312513423319100
   PubMed Web of Science ®Google Scholar
• GuJNoeAChandraPPharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)J Clin Pharmacol201050440141419934029
   PubMed Web of Science ®Google Scholar
• MistryNBWestheimASKjeldsenSEThe angiotensin receptor antagonist valsartan: a review of the literature with a focus on clinical trialsExpert Opin Pharmacother20067557558116553573
   PubMed Web of Science ®Google Scholar
• KsanderGMGhaiRDde JesusRDicarboxylic acid dipeptide neutral endopeptidase inhibitorsJ Med Chem19953810168917007752193
   PubMed Web of Science ®Google Scholar
• LangenickelTHDoleWPAngiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failureDrug Discov Today Ther Strateg201294e131e139
   Google Scholar
• VardenyOTachenyTSolomonSDFirst-in-class angiotensin receptor neprilysin inhibitor in heart failureClin Pharmacol Ther201394444544823872864
   PubMed Web of Science ®Google Scholar
• JessupMNeprilysin inhibition – a novel therapy for heart failureN Engl J Med2014371111062106425176014
   PubMed Web of Science ®Google Scholar
• McMurrayJJVPackerMDesaiASDual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)Eur J Heart Fail20131591062107323563576
   PubMed Web of Science ®Google Scholar
• SwedbergKKjekshusJEffects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)J Am Coll Cardiol198862260A66A
   Google Scholar
• [No authors listed]Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD InvestigatorsN Engl J Med199132552933022057034
   PubMed Web of Science ®Google Scholar
• McMurrayJJVPackerMDesaiASBaseline characteristics and treatment of patients in Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF)Eur J Heart Fail201416781782524828035
   PubMed Web of Science ®Google Scholar
• McMurrayJJVPackerMDesaiASAngiotensin-neprilysin inhibition versus enalapril in heart failureN Engl J Med201437111993100425176015
   PubMed Web of Science ®Google Scholar
• StilesSAfter sinking in, PARADIGM-HF critiqued at HFSA sessionsMedscape Available from: http://www.medscape.com/viewarticle/8322909252014
   Google Scholar
• Pablos-MendezABarrRGSheaSRun-in periods in randomized trials: implications for the application of results in clinical practiceJAMA199827932222259438743
   PubMed Web of Science ®Google Scholar
• SolomonSDZileMPieskeBThe angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 double-blind randomised controlled trialLancet201238098511387139522932717
   PubMed Web of Science ®Google Scholar
• ZileMRGottdienerJSHetzelSJPrevalence and significance of alterations in cardiac structure and function in patients with heart failure and a preserved ejection fractionCirculation2011124232491250122064591
   PubMed Web of Science ®Google Scholar
• RuilopeLMDukatABohmMLacourciereYGongJLefkowitzMPBlood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator studyLancet201037597221255126620236700
   PubMed Web of Science ®Google Scholar
• KarioKSunNChiangF-TEfficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled studyHypertension201463469870524446062
   PubMed Web of Science ®Google Scholar
• GansevoortRTCorrea-RotterRHemmelgarnBRChronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and preventionLancet2013382988933935223727170
   PubMed Web of Science ®Google Scholar
• MatsushitaKvan der VeldeMAstorBCAssociation of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysisLancet201037597312073208120483451
   PubMed Web of Science ®Google Scholar
• CaoZBurrellLMTikkanenIBonnetFCooperMEGilbertREVasopeptidase inhibition attenuates the progression of renal injury in subtotal nephrectomized ratsKidney Int200160271572111473654
   PubMed Web of Science ®Google Scholar
• BenigniAZojaCZatelliCVasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathyKidney Int20046651959196515496167
   PubMed Web of Science ®Google Scholar
• ISRCTN RegistryUK Heart and Renal Protection (UK HARP-III) Available from: http://www.isrctn.com/ISRCTN11958993Accessed January 26, 2015
   Google Scholar
• MukharjiJRudeREPooleWKRisk factors for sudden death after acute myocardial infarction: two-year follow-upJ Am Coll Cardiol19845413136
   Google Scholar
• [No authors listed]Risk stratification and survival after myocardial infarctionN Engl J Med198330963313366866068
   PubMed Web of Science ®Google Scholar
• PfefferMABraunwaldEMoyéLAEffect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarctionN Engl J Med1992327106696771386652
   PubMed Web of Science ®Google Scholar
• PittBRemmeWZannadFEplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarctionN Engl J Med2003348141309132112668699
   PubMed Web of Science ®Google Scholar
• Von LuederTGWangBKompaAWebbRJordaanPKrumHAngiotensin-receptor neprilysin-inhibition (ARNi) attenuates ischemic cardiac failure in vivo and angiotensin-II-induced cellular cardiac hypertrophy and fibrosisGlobal Heart201491 Suppl 1e237
   Google Scholar
• von LuederTGWangBHKompaARThe angiotensin-receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophyCirc Heart Fail201581717825362207
   PubMed Web of Science ®Google Scholar